Skip to content

Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa

Survey to Identify Burdens and Unmet Needs of EB Patients in the US

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03158662
Enrollment
150
Registered
2017-05-18
Start date
2017-04-02
Completion date
2017-06-30
Last updated
2017-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidermolysis Bullosa

Keywords

Epidermolysis Bullosa, Recessive Dystrophic, Simplex, Junctional Non-Herlitz

Brief summary

This survey intends to collect information on key aspects of life with epidermolysis bullosa (EB), including diagnostic journey, treatment, management, daily living challenges, and overall psycho-social, socio-economic, academic and family impact. Objectives: * To understand the unmet needs for people living with EB in the US * To assess the differences/similarities in the management/treatment of EB patients (including wound care, symptom management and other issues) * To assess the EB patients' and caregivers' perceptions of current management/treatment * To assess the challenges and the burden of daily living with EB * To understand EB diagnostic journey (the time to diagnosis and by what type of healthcare provider) * To identify professional disciplines involved in the diagnosis and management of EB * To understand the psycho-social, socio-economic, academic, and family impact of EB

Detailed description

Epidermolysis bullosa (EB) is a rare, often severe genetic disorder characterized by mechanical fragility and blistering or erosion of the skin, mucosa, or epithelial lining of other organs, in response to little or no apparent trauma. EB is chronic, potentially disfiguring, and in some cases fatal. Patients with EB have painful wounds and blisters that can lead to infection and scarring. There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears, sometimes from the slightest friction or trauma. There is currently no approved treatment for EB. Current standard of care consists of pain management and the bandaging and cleaning of open wounds to prevent infection. While there are a number of publications/guidance/consensus statements related to the diagnosis and management of EB from the point of view of the health-care provider/disease expert, there is a need for more research to define the key aspects of life with EB (i.e. diagnostic journey, treatment, management, daily living challenges, and overall disease burden) from the perspective of the patient.

Interventions

OTHERSurvey

Survey Study

Sponsors

Amicus Therapeutics
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Confirmed diagnosis of EB including subtype * Resident of the US * Informed Consent * Patient must be 18 years or older * If the survey is done by a caregiver, they must be a parent or legal guardian and must be 18 years or older to answer on behalf of a patient under 18 years or on behalf of a patient 18 years or older who is unable to answer for themselves. * Must participate in and complete a one hour telephone interview

Exclusion criteria

* Patient failing to meet the inclusion criteria above

Design outcomes

Primary

MeasureTime frame
Current quality of life burdens for EB patientsOutcome will be assessed immediately after subjects answer the questionnaire as this is a cross-sectional survey

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026